Taken together, SC-1 represents a triple-hit B-cell lymphoma cell line, in which IGH rearrangements target FL-specific oncogene BCL2, MYC, as well as a novel target at 17q21, together with fusion of BCL6 and MBNL1. This evidence concerns the gene MYC and B-cell non-Hodgkin lymphoma.